{"classes":[{"categories":[{"measurements":[{"comment":"Median was not achieved as no case of skin lesion was observed.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median was not achieved as no case of skin lesion was observed.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"61"}],"units":"Participants"}],"description":"Duration of skin lesion response was defined as the time from the first skin lesion response until the first skin lesion progression, defined as worsening of lesion by \\> 25% or more from baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received oral dose of everolimus 4.5 mg/m\\^2 daily as an initial starting dose to attain the whole blood trough concentrations in range of 5-15 ng/mL. Dose adjustments were permitted based on safety and whole blood trough concentrations.","id":"OG000","title":"Everolimus (Core Period)"},{"description":"Participants received oral dose of everolimus 4.5 mg/m\\^2 daily as an initial starting dose to attain blood trough concentrations in range of 5-15 ng/mL.","id":"OG001","title":"Everolimus (Extension Period)"}],"paramType":"MEDIAN","populationDescription":"The analysis was performed in the FAS population. Here, \"Number of participants analysed\" signifies everolimus treated responders with best overall skin lesion response during the core and extension period, respectively.","reportingStatus":"POSTED","timeFrame":"Baseline up to week 48 (end of core period), and end of extension period (up to 4 years)","title":"Duration of Skin Lesion Response in Everolimus Treated Participants","type":"SECONDARY","unitOfMeasure":"months"}